Core Viewpoint - Sanofi Pharmaceutical (01530) reported a mid-term performance for the six months ending June 30, 2025, showing a revenue of RMB 4.355 billion, a slight decrease of 0.77% year-on-year, while the profit attributable to shareholders increased by 24.61% to RMB 1.358 billion, with basic earnings per share at RMB 0.57 [1] Group 1: Company Performance - The company is recognized as a leading biotechnology firm in China, with extensive experience in the research, production, and marketing of biopharmaceutical products [1] - The core commercialized products include various biopharmaceuticals such as Tevaz, recombinant human erythropoietin products Yibiao and Saiboer, Yisaipu, and Saiputin, as well as the small molecule drug Mandi [1] - Tevaz is noted as the only commercialized recombinant human thrombopoietin product globally [1] Group 2: Market Position - According to IQVIA, Tevaz held a market share of 63.0% in the treatment market for thrombocytopenia in mainland China during the first half of 2025 [1] - The company has been a market leader in the rhEPO market in mainland China for over twenty years, with a total market share of 41.5% in the first half of 2025 [1] - Yisaipu is recognized as the first tumor necrosis factor α inhibitor product launched in the mainland market [1] - Mandi also holds a dominant position in the minoxidil market in mainland China [1] Group 3: Strategic Development - The company is expanding its treatment areas through internal research and development as well as multiple external strategic collaborations [1]
三生制药发布中期业绩 股东应占溢利13.58亿元 同比增长24.61%